#Toxoplasmosis sketchy micro pdf#
#Toxoplasmosis sketchy micro trial#

Seventy-nine patients with chronic hepatitis B were randomized to receive silymarin 140 mg three times a week for 4 weeks or placebo for the same duration. However, only the MHS score in group A showed a statistically significant improvements (p=0.02) (Table 2) The below table compares the baseline and post-treatment value of LFTs for groups A and B. The physical health related score and the mental health related score showed some improvement in both groups. The percentages of subjects who reduced their LFTs from baseline values were 47.5% for bilirubin, AST and ALT respectively and 45% for ALP. However, the differences were not statistically significant (p>0.05) respectively. In group B, the mean serum concentrations of liver enzymes were also reduced from baseline to post-treatment values except for AST and ALP. In group A, the mean serum concentration of liver enzymes was reduced from baseline to post-treatment values and this reduction was statistically significant for AST and ALT but not for bilirubin and ALP. The pre-treatment (baseline) values of the liver enzymes (Bilirubin, AST, ALT, ALP) when compared between the two groups was higher in group A but the difference was not statistically significant. In group A, 39 persons completed the study while 40 persons completed in group B. While in 2 persons, the reason for dropping out was not documented. Three in the treatment group and 2 in the placebo group. Mild adverse event (pruritus, headache, epigastric discomfort and throat irritation) was the reason for dropping out in 5 persons. Seventy-nine persons completed the study. Silymarin use was associated (p0.05) (Table 1). Results: Eighty-six persons were enrolled into the study.

Their liver function tests and HRQOL were assessed at baseline and post-treatment. Patients with chronic hepatitis B were randomized to receive silymarin or placebo for 4 weeks.

#Toxoplasmosis sketchy micro trial#

Methods: This was a double-blind randomized placebo-controlled trial conducted at the University of Calabar Teaching Hospital, Cross river state.

#Toxoplasmosis sketchy micro pdf#

View PDF Download PDF Tables & Figures AbstractД«ackground: Silymarin, an extract of milk thistle (silybum marianum) is widely used in the treatment of patients with chronic liver disease yet its beneficial effects remain controversial.ДЄim: To determine the effect of silymarin on liver biochemistry and health related quality of life (HRQOL) in treatment naГЇve patients with chronic hepatitis B infection. Visit for more related articles at Journal of Infectious Diseases & Therapy This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received JAccepted SeptemPublished September 30, 2014Д¬itation: Okonkwo Uchenna C, Aluka Anthony, Ezedinachi Emmanuel (2014) Effects of Silymarin on Treatment NaГЇve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial. 1278, Calabar, Cross river state, Nigeria Effects of Silymarin on Treatment NaГЇve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial Okonkwo Uchenna C 1 *, Aluka Anthony 2and Ezedinachi Emmanuel 1ДЎ Department of Internal Medicine, University of Calabar Teaching Hospital, Calabar, NigeriaДў Department of Family Medicine, University of Calabar Teaching Hospital, Calabar, Nigeria